DERRY based ActionSense is one of 15 companies who will be showcasing the North West’s ‘entrepreneurship and innovation’ when they travel to Boston Massachusetts next week as part of a joint collaboration between Councils in Derry/Strabane and Donegal.
The trip is part of the region’s strategy to promote inward investment and provide local businesses access to potential export opportunity.
ActionSense Ltd produces novel wearable technology to monitor and measure the angle of movement in the fingers with its first product targeted at aiding the assessment of Rheumatoid Arthritis and Oesteoarthritis.
In addition to the wearable device or ‘smart glove’ they design and supply intelligent software to monitor, record and analyse the data produced from the device for both patient users and clinicians.
Speaking ahead of the Boston trade mission, ActionSense CEO Dr Joan Condell who is based at the UU’s Intelligent Systems Research Centre, said:
“Currently, there is nothing on the market which caters for this important clinical need. The closest wearable glove technologies are in the gaming and virtual reality sector.
“The intelligent software data analytics within the ActionSense product is much more comprehensive and sophisticated than that provided by any related competitor.
“Our system provides real-time objective data analytics to assist and inform clinicians for quick and informed decision-making.
“Our combined product provides an advanced home-based rehabilitation tool which can be tailored to cover a number of alternative clinical needs besides Rheumatoid Arthritis and Oestoarthritis – such as post-Stroke mobility recovery, post-surgical mobility monitoring or Diabetes monitoring.
“The main reason for us participating in the North West trade delegation to Boston is that we would eventually hope to break into the US market.
“The trade mission will also help us to gain an insight into the US health and life sciences market; to better understand the legal and regulatory requirements for entering this marketplace. In addition, we are very keen to gain further wider contacts in the US as potential partners or distributors.
“We can offer companies there a unique opportunity to be at the cutting-edge of clinical assessment of Rheumatoid Arthritis and Oestoarthritis– as well as home-based rehabilitation monitoring tools and clinical data analytics.
“We will be delighted if we can establish key leads with potential partners for continued discussion as our ActionSense UK business evolves.
“A successful trip would also mean that we would have the main building blocks for a strategy for the route to market in the US.”